No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Phase 1 trial shows loncastuximab tesirine demonstrated significant response rates and an acceptable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

byKathleen Lau

May 21, 2021

in StudyGraphics

Combined cagrilintide and semaglutide for weight management well-tolerated in early clinical trials

RelatedReports

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Oncology

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

June 4, 2026

Pharma

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

June 3, 2026

Esmolol-induced heart rate reduction may aid in septic shock

Survivors of intensive care unit admissions may have increased risk of self-harm and suicide

Being overweight and obese associated with increased incidence of chronic kidney disease

2 Minute Medicine Rewind May 24, 2021

Standardized developmental screening of refugee children is recommended

Hand hygiene intervention to optimise soil-transmitted helminth infection control among primary school children found to be not effective

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports